Literature DB >> 15480668

Autologous stem cell transplantation in hematological malignancies.

Norbert-Claude Gorin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15480668     DOI： 10.1007/s00281-004-0172-4

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  97 in total

1.  High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome.

Authors:  N Feller; G J Schuurhuis; M A van der Pol; G Westra; G W D Weijers; A van Stijn; P C Huijgens; G J Ossenkoppele
Journal:  Leukemia       Date:  2003-01       Impact factor: 11.528

2.  Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia.

Authors:  S M Davies; N K Ramsay; J P Klein; D J Weisdorf; B Bolwell; J Y Cahn; B M Camitta; R P Gale; S Giralt; C Heilmann; P J Henslee-Downey; R H Herzig; R Hutchinson; A Keating; H M Lazarus; G A Milone; S Neudorf; W S Perez; R L Powles; H G Prentice; G Schiller; G Socié; M Vowels; J Wiley; A Yeager; M M Horowitz
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

3.  Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey.

Authors:  Vanderson Rocha; Myriam Labopin; Eliane Gluckman; Ray Powles; William Arcese; Andrea Bacigalupo; Josy Reiffers; Arturo Iriondo; Olle Ringdén; Tapani Ruutu; Francesco Frassoni
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

Review 4.  Autologous stem cell transplantation for adult acute leukemia.

Authors:  Norbert-Claude Gorin
Journal:  Curr Opin Oncol       Date:  2002-03       Impact factor: 3.645

5.  Ex vivo expansion of mafosfamide-purged PBPC products.

Authors:  I McNiece; C Civin; J Harrington; J Kellner; M Malehorn; J Turney; J Barber; R Jones
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

6.  Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.

Authors:  H C Kluin-Nelemans; V Zagonel; A Anastasopoulou; D Bron; K J Roozendaal; E M Noordijk; H Musson; I Teodorovic; B Maes; A Carbone; P Carde; J Thomas
Journal:  J Natl Cancer Inst       Date:  2001-01-03       Impact factor: 13.506

7.  Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  F Frassoni; M Labopin; R Powles; J Y Mary; W Arcese; A Bacigalupo; D Bunjes; E Gluckman; T Ruutu; U W Schaefer; J Sierra; J P Vernant; R Willemze; T de Witte; N C Gorin
Journal:  Lancet       Date:  2000-04-22       Impact factor: 79.321

8.  Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  O Ringdén; M Labopin; F Frassoni; G Sanz; F Demeocq; H Prentice; J Y Cahn; T Barbui; G Meloni; U Schaefer; J Reiffers; N Gorin
Journal:  Bone Marrow Transplant       Date:  1999-08       Impact factor: 5.483

9.  Autologous bone marrow transplantation with monoclonal antibody purged marrow for children with acute lymphoblastic leukemia in second remission. Spanish Working Party for BMT in Children.

Authors:  M S Maldonado; C Díaz-Heredia; I Badell; A Muñoz; J J Ortega; J Cubells; E Otheo; T Olive; C Canals; J Pérez-Oteyza
Journal:  Bone Marrow Transplant       Date:  1998-12       Impact factor: 5.483

Review 10.  A review of the proteasome inhibitor bortezomib in multiple myeloma.

Authors:  Paul G Richardson
Journal:  Expert Opin Pharmacother       Date:  2004-06       Impact factor: 3.889
View more
  2 in total

1.  Value of pretransplant pulmonary function tests in predicting pulmonary complications after autologous peripheral stem cell transplantation.

Authors:  Mohamad El-Khatib; Pierre Bou-Khalil; Ossama Abbas; Ali Salman; Ghassan Jamaleddine
Journal:  Lung       Date:  2007-10-19       Impact factor: 2.584

2.  Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients.

Authors:  P Quittet; P Ceballos; E Lopez; Z Y Lu; P Latry; C Becht; E Legouffe; N Fegueux; C Exbrayat; D Pouessel; V Rouillé; J P Daures; B Klein; J F Rossi
Journal:  Bone Marrow Transplant       Date:  2006-08       Impact factor: 5.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.